For research use only. Not for therapeutic Use.
Lapatinib-d4（Cat No.:S000495） is a deuterated form of lapatinib, where four hydrogen atoms are replaced with deuterium. Lapatinib is a targeted therapy drug used primarily in the treatment of breast cancer, particularly HER2-positive breast cancers. It functions as a dual tyrosine kinase inhibitor, blocking both HER2 and EGFR pathways, which are involved in cell growth and proliferation. The introduction of deuterium in Lapatinib-d4 increases the drug’s metabolic stability, enabling more detailed and accurate pharmacokinetic studies.
| Catalog Number | S000495 |
| CAS Number | 2122830-91-3 |
| Molecular Formula | C20H17D4F3N4O |
| Purity | ≥95% |
| IUPAC Name | 4,5,6,7-tetradeuterio-3-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1H-benzimidazol-2-one |
| InChI | InChI=1S/C20H21F3N4O/c21-20(22,23)15-4-3-5-16(14-15)26-11-8-25(9-12-26)10-13-27-18-7-2-1-6-17(18)24-19(27)28/h1-7,14H,8-13H2,(H,24,28)/i1D,2D,6D,7D |
| InChIKey | PPRRDFIXUUSXRA-ZEJCXXMWSA-N |
| SMILES | C1CN(CCN1CCN2C3=CC=CC=C3NC2=O)C4=CC=CC(=C4)C(F)(F)F |
